Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001550 | Apr 1996 → May 2002 | myopathy, stiff-person syndrome | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “This study will attempt to determine the effectiveness of intravenous immunoglobulin (IVIg) for the treatment of Stiff-mann Syndrome.” NCT00001550 ↗ |
| Known as | IVIg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001550 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIg)” NCT00001550 ↗ |
| Route | Intravenous | “intravenous immunoglobulin (IVIg)” NCT00001550 ↗ |